Grove Biopharma, Inc. | $30,000,000 | (Apr 25, 2025)
Northwood | $30,000,000 | (Apr 25, 2025)
Steadily Insurance Company | $30,000,000 | (Apr 25, 2025)
Certified by Founder
Lodge
DermBiont, Inc.
start up
United States
- Boston, Massachusetts
- 25/10/2023
- Series B
- $35,200,000
DermBiont’s mission is to become the world’s leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root causes of skin diseases through the development of targeted small molecule therapeutics with well-defined mechanisms of action and biotherapeutics that repair an imbalance of the microbiome. The company’s targeted topical therapeutics pipeline includes SM-020 for the treatment of seborrheic keratosis, SM-030 for the treatment of hyperpigmentation disorders of the skin, and DBI-001 & DBI-002 for the treatment of atopic dermatitis, tinea pedis, and onychomycosis. For more information, please visit www.dermbiont.com.
- Industry Biotechnology Research
- Website https://www.dermbiont.com/
- LinkedIn https://www.linkedin.com/company/dermbiont/about/
Alternative Payments | $22,000,000 | (Apr 25, 2025)
Listen Labs | $27,000,000 | (Apr 25, 2025)
Lace | $14,000,000 | (Apr 25, 2025)
Ravenna | $15,000,000 | (Apr 25, 2025)
ChEmpower Corporation | $18,700,000 | (Apr 25, 2025)
Theo | $20,000,000 | (Apr 25, 2025)
Isembard | $9,000,000 | (Apr 25, 2025)
Electra(US) | $186,000,000 | (Apr 25, 2025)